quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·39d
PRRelease
Eledon Pharmaceuticals Inc. logo

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine

ELDN· Eledon Pharmaceuticals Inc.
Health Care
Original source

Companies

  • ELDN
    Eledon Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Jun 18UpdateH.C. Wainwright$9.00
  • Jan 28UpdateGuggenheim$9.00
  • May 13UpdateCantor Fitzgerald$15.00
  • Nov 24UpdateHC Wainwright & Co.$25.00

Related

  • PR4d
    NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
  • PR17d
    Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Eledon Pharmaceuticals Inc.
  • PR35d
    Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
  • SEC35d
    SEC Form 10-K filed by Eledon Pharmaceuticals Inc.
  • SEC35d
    Eledon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR45d
    Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
  • PR46d
    NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022